Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced ...
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
Guggenheim has initiated coverage of Metsera (MTSR) with a buy rating, citing the company's obesity drug candidates. Read ...
Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up ...
Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug ...
Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...
BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...
Guggenheim initiated coverage of Metsera (MTSR) with a Buy rating and $56 price target The firm sees a “highly promising multi-billion ...
We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a ...
Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...
Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...
Aadvark, which will list on the Nasdaq under the ticker “AARD” Feb. 13, will have the opportunity to bring in roughly $14.1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results